Pfizer-Allergan deal a prelude to splitting company
(Reuters) — A Pfizer (NYSE:PFE) merger with Ireland-based Allergan (NYSE: AGN), in addition to providing tax benefits, would bolster the U.S. drugmaker’s growth prospects should it decide to sell or spin off its portfolio of products that have gone off patent.
Many Wall Street analysts believe Pfizer will decide to split late next year, after compiling 3 years of financial data treating its “established products” division, which sells generic medicines, and its “innovative” patent-protected medicines unit, as if they were separate companies.
Such a split would dramatically boost the compan...
Source: Mass Device - November 6, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Mergers & Acquisitions Pharmaceuticals Allergan Inc. Pfizer Inc. Source Type: news
BOTOX cost effective for overactive bladder
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 1, 2015 Category: Drugs & Pharmacology Source Type: news
Taris reboots with $32m round for bladder tech
A year after dealing its Liris bladder treatment to Allergan in a deal worth up to $588 million, Taris Biomedical raised another $32 million to put toward the implant, which is designed to deliver drugs directly to the bladder.
Allergan paid $67.5 million in cash in August 2014 for Liris, a drug-device combination designed to deliver lidocaine to treat interstitial cystitis, or bladder pain syndrome. The deal also included $295 million in development milestones and another $225 million in commercial milestones.
Today Taris said it’s planning to investigate other treatments using the same implant used in Liris, f...
Source: Mass Device - October 27, 2015 Category: Medical Equipment Authors: Brad Perriello Tags: Drug-Device Combinations Funding Roundup Taris Biomedical Venture Capital/Private Equity Source Type: news
StimGuard wins another IDE nod for bladder treatment trial
StimGuard said it won another FDA Investigational Device Exemption to run a clinical trial of its percutaneously implantable device to treat urgency urinary incontinence as a result of refractory overactive bladder syndrome.
The StimGuard device utilizes a 1.3mm microchip neurostimulator designed to be implanted non-surgically with a needle. The stimulator communicates with a small external transmitter that can be worn discretely and requires no physical contact with the skin.
“If successfully trialed, the StimGuard technology would allow neuromodulation to be offered to patients in an office setting, which has never...
Source: Mass Device - October 8, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Clinical Trials Food & Drug Administration (FDA) Regulatory/Compliance Urology StimGuard Source Type: news
Medtronic wins expanded FDA PMA for Verify system
Medtronic (NYSE:MDT) said yesterday it won an expanded FDA premarket approval for its Verify system for testing patients for use with its Interstim bladder or bowel control sacral neuromodulation device during basic evaluations.
The Verify allows patients with overactive bladder, non-obstructive urinary retention or bowel incontinence to test Interstim system for 3-7 days before making a long-term commitment, the Fridley, Minn.-based company said.
“Many patients suffering from OAB have failed multiple treatments and the Verify system for basic evaluations uses new technology to make it easier and faster for pati...
Source: Mass Device - October 1, 2015 Category: Medical Equipment Authors: Fink Densford Tags: Food & Drug Administration (FDA) Neuromodulation/Neurostimulation Regulatory/Compliance Medtronic Source Type: news
3 Bathroom Questions You're Too Embarrassed To Ask
We brought these questions to the experts so you don’t have to. "Is something wrong with me if I don't go number two every day?" Like snowflakes, everyone's bowel habits are unique. Some of us may go several times a day, and some just a couple of times a week, says gastroenterologist Rebekah Gross, MD, clinical assistant professor of medicine at NYU Langone Medical Center. That said, if you often feel bloated when it's not time for your period or notice a change in your regular pattern, it's a good idea to get checked out. "Why do I feel like I have to pee but can't?" Before you pee, your brain has to "grant perm...
Source: Healthy Living - The Huffington Post - July 6, 2015 Category: Consumer Health News Source Type: news
Overactive Bladder Increases Fall Risk in ElderlyOveractive Bladder Increases Fall Risk in Elderly
A look at Medicare claims data confirmed that having overactive bladder significantly elevates the risk for falls, but researchers were unable to show a significant risk reduction with treatment. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 8, 2015 Category: Consumer Health News Tags: Urology News Source Type: news
Overactive Bladder May Set Seniors Up for a Fall (CME/CE)
(MedPage Today) -- OAD diagnosis associated with higher odds of falls in Medicare population. (Source: MedPage Today Urology)
Source: MedPage Today Urology - May 19, 2015 Category: Urology & Nephrology Source Type: news
Botulinum Toxin A Injections Tame Overactive Bladder (CME/CE)
(MedPage Today) -- Injections controlled symptoms for up to 4 years (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - May 18, 2015 Category: Journals (General) Source Type: news
Botox Eases Overactive Bladder, 2 Studies Find
(Source: WebMD Health)
Source: WebMD Health - May 16, 2015 Category: Consumer Health News Source Type: news
Botox Eases Overactive Bladder, 2 Studies Find
Skin smoother brought relief for majority -- but not all -- of patients who got injections for urinary incontinenceSource: HealthDay
Related MedlinePlus Pages: Botox, Urinary Incontinence (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - May 15, 2015 Category: Consumer Health News Source Type: news
Bladder Trouble, Testosterone, Cancer Top AUA Meeting AgendaBladder Trouble, Testosterone, Cancer Top AUA Meeting Agenda
Results from a trial of a new combo for overactive bladder will be presented at the meeting, and new data on oral chemotherapies for prostate cancer and appropriate testosterone use will be shared. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 12, 2015 Category: Consumer Health News Tags: Urology News Source Type: news
StimGuard Receives FDA IDE Approval To Launch A U.S. Clinical Trial For A Revolutionary Wireless Device to Alleviate OAB Symptoms
StimGuard, a privately-held, pre-commercial stage medical device company, today announced that it has received FDA Investigational Device Exemption (IDE) approval to launch a clinical trial of the world’s first passive microsize implantable device for the treatment of Overactive Bladder Syndrome (OAB), utilizing wireless technology and placed completely through a needle. The clinical trial will launch in summer 2015. (Source: Medical Design Online News)
Source: Medical Design Online News - May 12, 2015 Category: Medical Equipment Source Type: news
Overactive Bladder: Anticholinergic Therapy Disappoints Overactive Bladder: Anticholinergic Therapy Disappoints
Anticholinergic treatment of overactive bladder in women is only modestly effective and rarely results in complete resolution of symptoms, according to a systematic review. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 12, 2015 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news
FDA OKs trial for StimGuard's bladder implant
StimGuard win approval from the FDA for an investigational device exemption trial of its wireless device to treat overactive bladder syndrome.
StimGuard said it won an investigational device exemption from the FDA for a clinical trial of its micro-size implantable device to treat overactive bladder syndrome. StimGuard said its system uses a small injectable microchip and an external transmitter and requires no invasive surgery to implant. The trial is slated to begin in summer 2015.
StimGuard, Stimwave TechnologiesNews Well, Clinical Trials, Investigational Device Exemption (IDE), Neuromodulation/Neur...
Source: Mass Device - May 11, 2015 Category: Medical Equipment Authors: Fink Densford Source Type: news
